News

7. January 2019

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

  • Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage...
28. January 2016

Probiodrug to Attend and Present at European and US Conferences in February 2016

20. January 2016

NOXXON PHARMA HOSTS KEY OPINION LEADER SYMPOSIUM

11. January 2016

Key patents granted for Probiodrug's pGlu-Abeta targeting monoclonal antibody program for the treatment of Alzheimer's disease

6. January 2016

Parlamentsgebäude in Belfast mit Calyxo Modulen

6. January 2016

Noxxon AG will an die Euronext

6. January 2016

Börse-Online - Branchenreport

6. January 2016

Probiodrug announces pricing of a EUR 13.5 million private placement of new shares

6. January 2016

Probiodrug gibt Kapitalerhöung bekannt

6. January 2016

Probiodrug AG to Publish its Third Quarter 2015 Business Update on November 19, 2015

Pages